Back to Studies

P1081 / 3 Regimens for HIV Infected Women initiating ARV regimens for PMTCT

A Randomized Trial to Evaluate the Virologic Response and Pharmacokinetics of Three Different Potent Regimens in HIV-infected Women Initiating HAART Between 28 and 36 Weeks of Pregnancy for the Prevention of Mother-to-Child Transmission

Study Status

Temporarily Closed (Paused) to Accrual and Study Agents/Products

DAIDS Number

10770

IND Number

111,297, 112,049

Clinical Research Manager

Data Manager

Drug Co. Representative

Field Representative

ICAB Representative

Immunologist

Investigator

Laboratory Data Manager (LDM)

Laboratory Technologist

Medical Officer

Neuropsychologist

Pharmacologist

Protocol Pharmacist

Senior Statistician

Statistician

Abstracts

Weight Gain with Raltegravir vs. Efavirenz During Pregnancy

Conference

CROI 2022

Study

P1081

Authors

Conrado Milani Coutinho, Meredith Warshaw, Geraldo Duarte, Alice Stek, Avy Violari, Cristina B Hofer, Jaime Deville, James Samwel Ngocho, José Pilotto, Mario Dias Correa Jr., Trevon Fuller, Nahida Chakhtoura, Mark Mirochnick, Esaú João

Randomized trial of raltegravir-ART vs. efavirenz-ART when initiated during pregnancy

Conference

CROI 2019

Study

P1081

Authors

M Mirochnick, DE Shapiro, L Morrison, L Frenkel, N Chakhtoura, GK Siberry, B Best, MLS Cruz, BT Mmbaga, JHS Pilotto, A Violari, S Prommas, E Joao for the NICHD P1081 protocol team